Statins: Pharmacokinetics, Pharmacodynamics and Cost-Effectiveness Analysis

Author(s): Gabriella Ricci, Marco Matteo Ciccone, Paola Giordano, Francesca Cortese*.

Journal Name: Current Vascular Pharmacology

Volume 17 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Cardiovascular diseases secondary to atherosclerosis are the primary causes of early death and disability worldwide and dyslipidaemia represents one of the most important modifiable risk factors. Among lipid abnormalities that define it, low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy, since multiple randomized controlled trials have shown the positive impact of its reduction on atherosclerosis development. For their ability to lower LDL-C levels, statins are the most studied drugs in cardiovascular disease prevention, of proven utility in slowing the progression or even determining regression of atherosclerosis. In addition, they have ancillary proprieties, with positive effects on the mechanisms involved in the development of atherosclerosis and cardiovascular morbidity and mortality, the so-called “pleiotropic mechanisms”. Although sharing the same mechanism of action, the different chemical and pharmacological characteristics of each kind of statins affect their absorption, bioavailability, plasma protein binding properties, excretion and solubility. In this overview, we analysed pharmacokinetic and pharmacodynamic mechanisms of this class of drugs, specifying the differences among the molecules, along with the economic aspects. Detailed knowledge of characteristics and differences of each kind of available statin could help the physician in the correct choice, based also on patient's clinical profile, of this essential tool with a demonstrated high cost-effectiveness both in primary than in the secondary prevention of cardiovascular disease.

Keywords: Hydroxymethyl glutaryl coenzyme A reductase, statins, low-density lipoprotein cholesterol, cardiovascular disease, atherosclerosis, statins.

[1]
Capuano V, Lamaida N, Capuano E, et al. Trend in prevalence of uncontrolled total serum cholesterol for cardio-cerebro-vascular disease in a Mediterranean area, 1988/89-2008/09. World J Cardiol 2013; 5: 420-5.
[2]
George SJ, Johnson J. Atherosclerosis molecular and cellular mechanisms. Weinheim: Wiley-VCH 2010; pp. 3-17.
[3]
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Atherosclerosis 2016; 253: 281-4.
[4]
Lim S, Sakuma I, Quon MI, Kon K. Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxid Redox Signal 2014; 10(20): 1286-99.
[5]
Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 2003; 4: 18.
[6]
Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot 1976; 1346-8.
[7]
Gunde-Cimerman N, Cimerman A. Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin. Exp Mycol 1995; 19: 1-6.
[8]
Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad, Ser B, Phys Biol Sci 2010; 86: 484-93.
[9]
Li JJ. Triumph of the heart: the story of statins in the story of statins. New York: Oxford University Press 2009; p. 224.
[10]
Yoshino G, Kazumi T, Kasama T, et al. Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics. Diabetes Res Clin Pract 1986; 2: 179-81.
[11]
Alberts AW. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology 1990; 77(Suppl. 4): 14-21.
[12]
National Library of Medicine's Medical Subject Headings. Fluvastatin. 2016. [cited 2018]. Available at: https://www.nlm.nih.gov/mesh/2016/mesh_browser/MBrowser.html
[13]
Associated Press. Lipitor becomes world's top-selling drug, Crain's New York Business. 2011. [cited 2018]. Available at: http://www.crainsnewyork.com/article/20111228/HEALTH_CARE/111229902/lipitor-becomes-worlds-top-selling-drug
[14]
Lee SH, Park S, Kang SM, Jang Y, Chung N, Choi D. Effect of atorvastatin monotherapy and low-dose atorvastatin/ezetimibe combination on fasting and postprandial triglycerides in combined hyperlipedemia. J Cardiovasc Pharmacol Ther 2012; 17: 65-71.
[15]
Blasetto JW, Stein EA, Brown WV, Chitra R, Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91: 3-10.
[16]
Mukhtar RY, Reid J, Reckless JP. Pitavastatin. Int J Clin Pract 2005; 59: 239-52.
[17]
Ooyen C, Zecca A, Bersino AM, Catapano AL. NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis 1999; 145: 87-95.
[18]
Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 2003; 18: 57-60.
[19]
Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-25.
[20]
Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Int J Endocrinol Metab 2015; 19: 554-62.
[21]
Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol (Review) 2003; 23: 1055-69.
[22]
Huang W, Shang WL, Li DH, Wu WW, Hou SX. Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4. Mol Cell Biochem 2012; 360: 71-7.
[23]
Cortese F, Gesualdo M, Cortese A, et al. Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res 2016; 107: 1-18.
[24]
Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003; 23: 729-36.
[25]
Baetta R, Lento S, Ghilardi S, et al. Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. Vascul Pharmacol 2015; 67-69: 38-47.
[26]
Sandhu K, Mamas M, Butler R. Endothelial progenitor cells: Exploring the pleiotropic effects of statins. World J Cardiol 2017; 26(9): 1-13.
[27]
Diamantis E, Kyriakos G, Quiles-Sanchez LV, Farmaki P, Troupis T. The anti-inflammatory effects of statins on coronary artery disease: an updated review of the literature. Curr Cardiol Rev 2017; 13: 209-16.
[28]
Serra N, Rosales R, Masana L, Vallvé JC. Simvastatin increases fibulin-2 expression in human coronary artery smooth muscle cells via RhoA/Rho-kinase signaling pathway inhibition. PLoS One 2015; 10: e0133875.
[29]
Nirogi R, Mudigonda K, Kandikere V. Chromatography-mass spectrometry methods for thequantitation of statins in biological samples. J Pharm Biomed Anal 2007; 44: 379-87.
[30]
Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84: 413-28.
[31]
Bottorff M, Hansten P. Long term safety of hepatic Hydroxymethyl Glutaryl Coenzyme AReductase Inhibitors: the role of metabolism - monograph for physicians. Arch Intern Med 2000; 160: 2273-80.
[32]
Ramkumar S, Raghunath A Raghunath S. Statin therapy: review of safety and potential side effects. Acta Cardiol Sin 2016; 32: 631-9.
[33]
Whayne TF. Problems and possible solutions for therapy with statins. Int J Angiol 2013; 22: 75-82.
[34]
Hodel C. Myopathy and rhabdomyolysis with lipid-lowering drugs. Toxicol Lett 2002; 128: 159-68.
[35]
Gouton M. Hypothyroidism, hypocholesterolemic agents and rhabdomyiolysis. Arch Mal Coeur Vaiss 1993; 86: 1761-4.
[36]
Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26.
[37]
Terrovitou CT, Milionis HJ, Elisaf MS. Acute rhabdomyiolysis after bezafibrate re-exposure. Nephron 1998; 78: 336-7.
[38]
Cziraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol 2013; 7: 102-8.
[39]
Gilad R, Lampl Y. Rhabdomyolysis induced by simvastatin and ketoconazole treatment. Clin Neuropharmacol 1999; 22: 295-7.
[40]
Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35: 26-31.
[41]
Stirling CM, Isles CG. Rhabdomyolysis due to simvastatin in a transplant patient: are some statins safer than others? Nephrol Dial Transplant 2001; 16: 873-4.
[42]
du Souich P, Roederer G, Dufour R. Myotoxicity of statins: Mechanism of action. Pharmacol Ther 2017; 175: 1-16.
[43]
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90.
[44]
Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3: 35-40.
[45]
Wang YC, Hsieh TC, Chou CL, Wu JL, Fang TC. Risks of adverse events following coprescription of statins and calcium channel blockers: a nationwide population-based study. Medicine (Baltimore) 2016; 95: e2487.
[46]
Mackay JW, Fenech ME, Myint KS. Acute rhabdomyolysis caused by combination therapy with atorvastatin and warfarin. Br J Hosp Med (Lond) 2012; 73: 106-7.
[47]
Mogyorósi A, Bradley B, Showalter A, Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin. J Intern Med 1999; 246: 599-602.
[48]
Barry M. Rosuvastatin-warfarin drug interaction. Lancet 2004; 363: 328.
[49]
Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-7.
[50]
Neubauer H, Gunesdogan B, Hanefeld C, Spiecker M, Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function - a flow cytometry study. Eur Heart J 2003; 24: 1744-9.
[51]
Wenaweser P, Eshtehardi P, Abrecht L, et al. A randomised determination of the effect of fluvastatin and atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial. Thromb Haemost 2010; 104: 554-62.
[52]
Bates ER, Lau WC, Angiolillo DJ. Clopidogrel-drug interactions. J Am Coll Cardiol 2011; 57: 1251-63.
[53]
Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43: 527-35.
[54]
Lee JW, Morris JK, Wald NJ. Grapefruit juice and statins. Am J Med 2016; 129: 26-9.
[55]
Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet 2013; 52: 815-31.
[56]
Fellström B, Holdaas H, Jardine AG, et al. Assessment of lescol in renal transplantation study investigators. effect of fluvastatin on renal end points in the assessment of lescol in renal transplant (ALERT) trial. Kidney Int 2004; 66: 1549-55.
[57]
Holdaas H, Fellström B, Cole E, et al. Assessment of lescol in renal transplantation (ALERT) Study Investigators. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929-36.
[58]
Kato R, Nishide M, Kozu C, et al. Is cyclosporine A transport inhibited by pravastatin via multidrug resistant protein 2? Eur J Clin Pharmacol 2010; 66: 153-8.
[59]
Holdaas H, Hagen E, Asberg A, et al. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients. Int J Clin Pharmacol Ther 2006; 44: 163-71.
[60]
Srinivas NR. The drug-drug interaction potential of rifampicin. Clin Ther 2008; 30: 1932-3.
[61]
Candrilli SD, Manjunath R, Davis KL, Gidal BE. The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy. Epilepsy Res 2010; 91: 260-6.
[62]
Eggertsen R, Andreasson A, Andrén L. Effects of treatment with a commercially available St John’s Wort product (Movina) on cholesterol levels in patients with hypercholesterolemia treated with simvastatin. Scand J Prim Health Care 2007; 25: 154-9.
[63]
Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-207.
[64]
Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009; 32: 1924-9.
[65]
Thakker D, Nair S, Pagada A, Jamdade V, Malik A. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf 2016; 25: 1131-49.
[66]
Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-42.
[67]
Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011; 57: 1535-45.
[68]
Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia 2006; 49: 1881-92.
[69]
Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: fourth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375-414.
[70]
Kanda M, Satoh K, Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003; 26: 1681-4.
[71]
FDA Drug Safety Communication. 2012. [cited 2018] Available at: www.fda.gov
[72]
Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ 2000; 321: 983-6.
[73]
Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000; 102: 1893-900.
[74]
Sever PS, Dahlöf B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
[75]
Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian simvastatin survival study group. N Engl J Med 1997; 336: 332-6.
[76]
Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000; 132: 769-79.
[77]
Johannesson M. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001; 22: 919-25.
[78]
Grover SA, Coupal L, Zowall H, Dorais M. Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 2000; 102: 722-7.
[79]
Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Heart protection study collaborative group. cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20,536 individuals. Lancet 2005; 365: 1779-85.
[80]
Franco OH, Peeters A, Looman CW, Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health 2005; 59: 927-33.
[81]
Ward S, Lloyd JM, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11: 1-160.
[82]
Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769-81.
[83]
White CM. A review of the Pharmacologic and pharmacokinetic aspect of rosuvastation. J Clin Pharmacol 2002; 42(9): 963-70.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 3
Year: 2019
Page: [213 - 221]
Pages: 9
DOI: 10.2174/1570161116666180706144824
Price: $58

Article Metrics

PDF: 73
HTML: 3
EPUB: 1
PRC: 1